基于Web of Science的药品说明书适老化研究文献计量学分析

李茜茜; 陆浩; 武明芬; 赵志刚

doi:10.6039/j.issn.1001-0408.2024.02.19

您当前的位置：

首页 >

文章列表页 >

基于Web of Science的药品说明书适老化研究文献计量学分析

药师与药学服务 | 更新时间：2024-01-24

- 基于Web of Science的药品说明书适老化研究文献计量学分析
- Bibliometric analysis of drug package insert adaptation for the elderly based on Web of Science
- 中国药房 2024年35卷第2期页码：231-236
- 作者机构：
  
  1.首都医科大学附属北京胸科医院药学部，北京;101149
  2.壹正医院管理发展（北京）中心，北京　100020
  3.首都医科大学附属北京天坛医院药学部，北京　100070
- 作者简介：
  
  药师，硕士。研究方向：临床药学。E-mail：lixixi1995@163.com
  主任药师，教授，博士生导师。研究方向：药事管理、临床药理。E-mail：1022zzg@sina.com
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.02.19
  中图分类号： R95
- 纸质出版日期：2024-01-30，
  
  收稿日期：2023-05-25，
  
  修回日期：2023-11-28，
扫描看全文
李茜茜,陆浩,武明芬等.基于Web of Science的药品说明书适老化研究文献计量学分析 ^Δ[J].中国药房,2024,35(02):231-236.

LI Xixi,LU Hao,WU Mingfen,et al.Bibliometric analysis of drug package insert adaptation for the elderly based on Web of Science[J].ZHONGGUO YAOFANG,2024,35(02):231-236.
李茜茜,陆浩,武明芬等.基于Web of Science的药品说明书适老化研究文献计量学分析 ^Δ[J].中国药房,2024,35(02):231-236. DOI： 10.6039/j.issn.1001-0408.2024.02.19.

LI Xixi,LU Hao,WU Mingfen,et al.Bibliometric analysis of drug package insert adaptation for the elderly based on Web of Science[J].ZHONGGUO YAOFANG,2024,35(02):231-236. DOI： 10.6039/j.issn.1001-0408.2024.02.19.

摘要

目的

探索药品说明书适老化的研究热点，为我国药品说明书适老化发展提供依据。

方法

在Web of Science核心合集数据库中检索2012－2022年发表的老年人使用药品说明书的相关英文文献，应用VOSviewer和CiteSpace软件进行文献计量学分析，探索该领域的研究热点，并总结该领域发展的障碍和解决措施。结果与

结论

本研究共收集到药品说明书适老化相关文献335篇，来自51个国家（地区）的819个研究机构，涉及2 174位作者。近10年，药品说明书适老化研究发展趋缓，美国和日本等发达国家占该领域的主导地位，其中美国西北大学Wolf等学者的发文量最大（12篇）。老年人用药风险管理、药品说明书中老年用药信息的更新，以及老年人对药品说明书的理解和依从及其影响因素等是该领域的研究热点。药品说明书适老化发展中相关障碍的解决措施包括提高药品说明书的可视性、可读性，填补药品说明书中老年用药信息等。我国可借鉴其他国家的经验和方法，针对我国人口特点开展老年药品说明书影响因素的调查及老年用药的药动学研究，多维度提高老年患者用药的安全性。

Abstract

OBJECTIVE

To explore the hotspots of aging adaptation of drug package inserts， and to provide evidence for the development of aging adaptation of drug package inserts in China.

METHODS

The relevant English literature on drug package inserts for the elderly published from 2012 to 2022 was retrieved from Web of Science Core Collection； bibliometric analysis was performed by using VOSviewer and CiteSpace software， to explore research hotspots in this field， and summarize obstacles and solutions for the development of this field.

RESULTS

CONCLUSIONS

This study collected a total of 335 literature related to the aging adaption of drug package inserts， from 819 research institutions in 51 countries （regions）， involving 2 174 authors. The research development of drug package insert adaptation for the elderly has slowed down in the past decade， and developed countries such as the United States and Japan dominate this field. Authors such as Wolf from Northwestern University in the United States， have the largest number of publications（12 literature）. The research focuses in this field include the risk management of medication for the elderly， the updating of medication information for the elderly in drug package inserts， and the understanding and compliance of the elderly with drug package inserts and their influencing factors. The solutions to related obstacles in the development of aging adaption in drug package inserts include improving the visibility and readability of drug package inserts， filling in the information on elderly medication in drug package inserts， and so on. China can learn from the experiences and methods of other countries， conduct investigations into the influencing factors of elderly package inserts and pharmacokinetic studies based on the characteristics of the Chinese population， and improve the safety of medication for elderly patients in multiple dimensions.

关键词

药品说明书适老化文献计量学用药安全老年人

Keywords

aging adaptionbibliometricsmedication safetythe elderly

references

高语晨，杨建红，赵紫楠，等. 美国处方药患者说明书管理制度研究[J]. 中国新药杂志，2022，31（9）：825-831.

GAO Y C，YANG J H，ZHAO Z N，et al. Study on the management system of patient labeling for prescription drugs in the US[J]. Chin J N Drugs，2022，31（9）：825-831.

罗太敏，李婷，倪倩，等. 我院老年住院患者潜在不适当用药情况的分析[J]. 中国药学杂志，2022，57（4）：315-320.

LUO T M，LI T，NI Q，et al. Analysis of potential inappropriate medication in elderly inpatients in our hospital[J]. Chin Pharm J，2022，57（4）：315-320.

闫园园，唐红波，阴赪宏，等. 基于CiteSpace的国内外妊娠期用药研究文献分析[J]. 中国药房，2020，31（10）：1239-1246.

YAN Y Y，TANG H B，YIN C H，et al. Literature analysis of domestic and foreign drug use in pregnancy period based on CiteSpace[J]. China Pharm，2020，31（10）：1239-1246.

XIE C T，GU Y H，WANG Y N，et al. Research status and hotspots of medication safety in older adults：a bibliome-tric analysis[J]. Front Public Health，2022，10：967227.

FDA. Geriatric information in human prescription drug and biological product labeling guidance for industry[BE/OL]. （2020-09-15）[2023-03-03]. https：//www.fda.gov/regulatory-information/search-fda-guidance-documents/geria-tric-information-human-prescription-drug-and-biological-product-labeling-guidance-industryhttps://www.fda.gov/regulatory-information/search-fda-guidance-documents/geria-tric-information-human-prescription-drug-and-biological-product-labeling-guidance-industry.

萧惠来. 美国食品药品管理局（FDA）对药品说明书中老年用药信息的要求及启示[J]. 药物评价研究，2021，44（2）：305-313.

XIAO H L. FDA’s requirements for geriatric information in drug labeling and its enlightenment[J]. Drug Eval Res，2021，44（2）：305-313.

SAHM L J，WOLF M S，CURTIS L M，et al. What’s in a label? An exploratory study of patient-centered drug instructions[J]. Eur J Clin Pharmacol，2012，68（5）：777-782.

WOLF M S，DAVIS T C，CURTIS L M，et al. A patient-centered prescription drug label to promote appropriate medication use and adherence[J]. J Gen Intern Med，2016，31（12）：1482-1489.

BAILEY S C，NAVARATNAM P，BLACK H，et al. Advancing best practices for prescription drug labeling[J]. Ann Pharmacother，2015，49（11）：1222-1236.

FEUFEL M A，RAUWOLF G，MEIER F C，et al. Heuristics for designing user-centric drug products：lessons learned from human factors and ergonomics[J]. Br J Clin Pharmacol，2020，86（10）：1989-1999.

BAILEY S C，PANDIT A U，YIN S，et al. Predictors of misunderstanding pediatric liquid medication instructions[J]. Fam Med，2009，41（10）：715-721.

MCCARTHY D M，RUSSELL A M，EIFLER M R，et al. Implementation fidelity of patient-centered prescription label to promote opioid safe use[J]. Pharmacoepidemiol Drug Saf，2019，28（9）：1251-1257.

MALHOTRA R，SUPPIAH S，TAN Y W，et al. Validation of pharmaceutical pictograms among older adults with limited English proficiency[J]. Patient Educ Couns，2022，105（4）：909-916.

MERKS P，CAMERON J D，BALCERZAK M，et al. Evaluation of a pharmacist-led intervention to improve medication adherence in patients initiating dabigatran treatment：a comparison with standard pharmacy practice in Poland[J]. BMC Prim Care，2022，23（1）：210.

NASUHARA Y，SAKUSHIMA K，OKI H，et al. Analysis of the implementation of blood tests specified in the packa-ge insert after prescription of thiamazole[J]. J Patient Saf，2020，16（1）：24-29.

CURTIS L M，MULLEN R J，RUSSELL A，et al. An efficacy trial of an electronic health record-based strategy to inform patients on safe medication use：the role of written and spoken communication[J]. Patient Educ Couns，2016，99（9）：1489-1495.

WOLF M S，TAITEL M S，JIANG J Z，et al. Prevalence of universal medication schedule prescribing and links to adherence[J]. Am J Health Syst Pharm，2020，77（3）：196-205.

SHIMAMURA H，YAMADA H，OKADA N，et al. A standard intervention practice to promote appropriate lamotrigine therapy by pharmacists[J]. Biol Pharm Bull，2018，41（4）：465-469.

SAKURADA H，KAWASE Y，ASANO H，et al. Analysis of the necessity of serum electrolyte monitoring for up to eight weeks after the completion of anti-epidermal growth factor receptor antibody administration[J]. Pharmazie，2016，71（7）：402-407.

YAMAMOTO H，HABU Y，YANO I，et al. Comparison of the effects of azole antifungal agents on the anticoagulant activity of warfarin[J]. Biol Pharm Bull，2014，37（12）：1990-1993.

HA D，LEE S E，SONG I，et al. Comparison of signal detection of tumour necrosis factor-α inhibitors using the Korea Adverse Events Reporting System Database，2005-2016[J]. Clin Rheumatol，2020，39（2）：347-355.

KADOWAKI T，INAGAKI N，WATADA H，et al. Real-world evidence of treatment with teneligliptin/canagliflozin combination tablets for type 2 diabetes mellitus：a post-marketing surveillance in Japan[J]. Adv Ther，2022，39（4）：1642-1658.

YU H，NYSAK S，GARG N，et al. ODAE：ontology-based systematic representation and analysis of drug adverse events and its usage in study of adverse events given different patient age and disease conditions[J]. BMC Bioinformatics，2019，20（Suppl 7）：199.

SHAHABI P，SCHEINFELDT L B，LYNCH D E，et al. An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance[J]. Thromb Haemost，2016，116（2）：337-348.

WEINER D，POWELL J R，PATTERSON J H，et al. Leveraging a previously published population pharmacokinetic model to predict rivaroxaban exposure in real-world patients[J]. J Clin Pharmacol，2022，62（12）：1518-1527.

CATTANEO D，FUSI M，COZZI V，et al. Supra-therapeutic linezolid trough concentrations in elderly patients：a call for action?[J]. Clin Pharmacokinet，2021，60（5）：603-609.

范燕，夏东胜. 我国药品说明书老年人用药标示的问题与对策[J]. 中国药物警戒，2016，13（6）：341-343，363.

FAN Y，XIA D S. Problems and countermeasures of labe-ling contents of using in the elderly in medicine instructions in China[J]. Chin J Pharmacovigil，2016，13（6）：341-343，363.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

我院321 例老年人药品不良反应报告分析

我院2009－2011年老年真菌感染菌种分布及其对抗真菌药敏感性分析

牛痘疫苗致炎兔皮提取物注射液联合阿昔洛韦治疗老年带状疱疹的临床观察

芪蓉润肠口服液联合乳果糖治疗高龄老年功能性便秘的临床疗效观察

老年人潜在不合理用药的评估标准